ijms-logo

Journal Browser

Journal Browser

Novel Therapeutics and Therapeutic Resistance in Hematological Malignancy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1417

Special Issue Editors

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The last few years have ushered in a new era of hematological malignancy research; the advent and approval of multiple targeted therapies and an improved understanding of patient immune systems have resulted in major progress in the development of immune therapies, including monoclonal antibodies with and without conjugated toxins (bacterial or chemical), bispecific T-cell engagers and DART antibodies, immune-checkpoint-based therapies, and CAR-T cell approaches.

At the same time, tumor biology has also seen recent advancements, leading to new combinations of drugs and novel therapies.

The numerous ongoing trials evaluating these therapies, with well-designed correlative interrogation of the immune system in patients treated in such trials, will further enhance our understanding of immune therapies with both single-agent and combination approaches.

This Special Issue will focus on personalized medicine in hematology, the efficacy of novel therapeutics, and promising combination approaches for further improving patient treatment outcomes.

Dr. Claudio Cerchione
Dr. Giovanni Martinelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • hematology
  • hematological malignancies
  • novel agents
  • target therapy
  • multiple myeloma
  • leukemia
  • acute leukemia
  • chronic leukemia
  • non-Hodgkin lymphoma
  • Hodgkin lymphoma

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 6974 KiB  
Article
5-Aza-2′-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential
by Karolina Łuczkowska, Piotr Kulig, Klaudia Rusińska, Bartłomiej Baumert and Bogusław Machaliński
Int. J. Mol. Sci. 2023, 24(23), 16780; https://doi.org/10.3390/ijms242316780 - 26 Nov 2023
Cited by 2 | Viewed by 827
Abstract
Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development [...] Read more.
Multiple myeloma (MM) is a plasma cell malignancy that accounts for 1% of all cancers and is the second-most-common hematological neoplasm. Bortezomib (BTZ) is a proteasome inhibitor widely implemented in the treatment of MM alone or in combination with other agents. The development of resistance to chemotherapy is one of the greatest challenges of modern oncology. Therefore, it is crucial to discover and implement new adjuvant therapies that can bypass therapeutic resistance. In this paper, we investigated the in vitro effect of methylation inhibitor 5-Aza-2′-deoxycytidine on the proliferative potential of MM cells and the development of resistance to BTZ. We demonstrate that alterations in the DNA methylation profile are associated with BTZ resistance. Moreover, the addition of methylation inhibitor 5-Aza-2′-deoxycytidine to BTZ-resistant MM cells led to a reduction in the proliferation of the BTZ-resistant phenotype, resulting in the restoration of sensitivity to BTZ. However, further in vitro and ex vivo studies are required before adjuvant therapy can be incorporated into existing treatment regimens. Full article
Show Figures

Figure 1

Back to TopTop